Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 5/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3324696 | 0.93 | JAK2 (0.48) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL26633654 | 0.92 | JAK2 (0.47) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL26633657 | 0.91 | JAK2 (0.46) | JAK2JAK1GPR119OPRD1OPRK1 | |
| SCHEMBL5874204 | 0.86 | GPR119 (0.47) | JAK2JAK1CYP11B2GPR119SCD5 | |
| SCHEMBL5874046 | 0.81 | JAK2 (0.47) | JAK2JAK1CYP11B2GPR119SCD5 | |
| SCHEMBL31566836 | 0.80 | CYP11B2 (0.47) | CYP11B2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2529921 | 0.80 | CA12 (0.54) | GPR119OPRD1OPRK1 | |
| SCHEMBL348952 | 0.80 | CYP11B2 (0.47) | JAK2JAK1CYP11B2PDE4APDE4B | |
| SCHEMBL3591187 | 0.79 | GPR119 (0.51) | JAK2JAK1CYP11B2GPR119OPRD1 | |
| SCHEMBL22509312 | 0.79 | OPRM1 (0.55) | JAK2JAK1GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7012144-B2 | Quinolone carboxylic acid derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2006-03-14 | — | — | US | disclosed |
| US-20030130302-A1 | Quinolone carboxylic acid derivatives | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130302-A1 | Quinolone carboxylic acid derivatives | CYCS, CBR3, HCCS | JAK2 2064/4885JAK1 1324/4885CYP11B2 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.